Evidence mapPaperPMID 41683321Full record

ReviewNutrients2026

Vitamin D in Cardiovascular Medicine: From Molecular Mechanisms to Clinical Translation.

Fahimeh Varzideh, Pasquale Mone, Urna Kansakar, Gaetano Santulli

Abstract readReview
In one paragraph

Review in Nutrients, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Fahimeh VarzidehSchool of Medicine, City University of New York, Manhattan, NY 10031, USA.
Pasquale MoneCasa di Cura "Clinica Montevergine", 83013 Mercogliano, Avellino, Italy.
Urna KansakarSchool of Medicine, City University of New York, Manhattan, NY 10031, USA.
Gaetano SantulliSchool of Medicine, City University of New York, Manhattan, NY 10031, USA.ORCID 0000-0001-7231-375X

Funding

REGULATION OF THE INSULIN RECEPTOR KINASER01DK033823 · UNIVERSITY OF IOWA · 1986 to 2004
$1.7M
Beta Cell Intracellular Calcium and DiabetesR01DK123259 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI Gaetano Santulli · 2022 to 2023
$840k
Caspase-9 as a nodal point connecting necrotic and apoptotic cell death in myocardial infarctionR01HL164772 · ALBERT EINSTEIN COLLEGE OF MEDICINE · 2025 to 2025
$622k
Post-doctoral trainee development into independent investigators under senior scientists mentorship (PODIUM)T32HL172255 · ALBERT EINSTEIN COLLEGE OF MEDICINE · 2025 to 2025
$323k
NHLBI NIH HHS R01 HL146691NHLBI NIH HHS R01 HL159062NHLBI NIH HHS R01 HL164772NHLBI NIH HHS T32 HL172255NIDDK NIH HHS R01 DK033823NIDDK NIH HHS R01 DK123259
6 · The paper itself

Abstract

Vitamin D, a fat-soluble secosteroid traditionally recognized for skeletal health, exerts pleiotropic effects on cardiovascular physiology and disease. Circulating 25-hydroxyvitamin D [25(OH)D], the principal biomarker of vitamin D status, is frequently suboptimal worldwide, particularly in older adults, individuals with darker skin pigmentation, and populations at higher latitudes. Observational studies consistently associate low 25(OH)D concentrations with increased risk of hypertension, atherosclerosis, myocardial infarction, heart failure, arrhythmias, stroke, and cardiovascular mortality. Mechanistic investigations have revealed that vitamin D modulates cardiomyocyte calcium handling, endothelial function, vascular smooth muscle proliferation, inflammation, oxidative stress, and renin-angiotensin-aldosterone system activity, establishing biologically plausible links to cardiovascular outcomes. Despite these associations, large randomized trials of vitamin D supplementation have failed to demonstrate reductions in major cardiovascular events, likely due to heterogeneity in baseline status, dosing regimens, intervention timing, genetic variability, and underlying comorbidities. Vitamin D may function more effectively as a biomarker of cardiovascular risk rather than a universal therapeutic agent, with deficiency reflecting systemic vulnerability rather than acting as a dominant causal factor. Emerging evidence supports precision approaches targeting individuals with severe deficiency, high renin activity, early endothelial dysfunction, or specific genetic profiles, potentially in combination with lifestyle or pharmacologic interventions. Future research should focus on defining optimal dosing strategies, intervention timing, and mechanistic biomarkers to identify subpopulations most likely to benefit, integrating vitamin D therapy into multifaceted cardiovascular prevention frameworks. This systematic review synthesizes molecular, observational, and clinical trial evidence, critically evaluating the current understanding of vitamin D in cardiovascular medicine and highlighting opportunities for targeted, personalized interventions. Vitamin D represents a complex, context-dependent modulator of cardiovascular health, offering both prognostic insight and potential therapeutic value when appropriately applied.

Indexed as

Cardiovascular DiseasesVitamin DVitamin D DeficiencyAnimalsBiomarkersDietary SupplementsHumans25-hydroxyvitamin DBiomarkersVitamin Dcardiologyendocrinologykidneymetabolismpharmacologyvitamin D

Identifiers

PMID41683321
PMCPMC12899724

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.